An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

NCT06204302 · clinicaltrials.gov ↗

COMPLETED

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-metastatic Prostate Cancer
Non-metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Darolutamide (Nubeqa, BAY1841788)
DRUG: Enzalutamide
DRUG: Apalutamide

Sponsor

Bayer